<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00721123</url>
  </required_header>
  <id_info>
    <org_study_id>WA18695</org_study_id>
    <nct_id>NCT00721123</nct_id>
  </id_info>
  <brief_title>A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>Long-term Extension Study of Safety During Treatment With Tocilizumab (MRA) in Patients Completing Treatment in WA17822</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label, international multi-center extension study WA18695 was designed to assess
      the long term safety of tocilizumab in patients who had moderate to severe active rheumatoid
      arthritis (RA). Patients enrolled in the WA18695 study had previously received treatment in
      the 24-week, placebo-controlled, Phase III Study WA17822. Eligible patients were assigned to
      treatment with 8 mg/kg tocilizumab every 4 weeks for a maximum of 5 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this extension study was to assess the long-term safety of 8 mg/kg
      tocilizumab with regard to adverse events (AEs) and laboratory result abnormalities.

      The secondary objectives were as follows:

        -  To explore the possibility of reducing concomitant steroid treatment

        -  To determine the long-term efficacy of 8 mg/kg tocilizumab with regard to reduction in
           signs and symptoms

        -  To better understand and predict tocilizumab efficacy, response, safety, and progression
           of rheumatoid arthritis (RA) and associated diseases with regard to its effect on
           biomarkers

      No viable biomarkers for TCZ treatment effects were identified from the controlled studies.
      There were, therefore, no biomarkers that warranted further investigation in long-term
      studies, so no biomarker data are reported.

      The extension study WA18695 was an open-label, international multi-center study in patients
      with moderate to severe active rheumatoid arthritis (RA) who had completed treatment in the
      24 weeks placebo-controlled Phase III study WA17822. Patients entering WA17822 had an
      inadequate response to methotrexate (MTX), and, during WA17822, patients had received
      treatment with intravenous infusions of tocilizumab 4 mg/kg, 8 mg/kg, or placebo every 4
      weeks with background MTX therapy.

      All patients who completed the planned course of treatment or escape therapy in the WA17822
      study were eligible to enter the WA18695 long-term extension study, where they were assigned
      to treatment with 8 mg/kg RoActemra/Actemra plus MTX. The dose of RA medications such as MTX
      and nonsteroidal anti-inflammatory drugs (NSAIDs), but excluding corticosteroids, was to be
      kept stable for the first 48 weeks of the WA18695 study. During this time dose reductions in
      these treatments were only allowed as clinically required for safety reasons. After week 48,
      the administration of disease-modifying antirheumatic drugs (DMARDs) and NSAIDs could be
      changed, according to the investigator's practice and as tolerated by the patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event (AE) Summary Over Time</measure>
    <time_frame>through 264 Weeks</time_frame>
    <description>The number of participants experiencing at least one adverse event (AE) is recorded for each 12-month time period, with multiple occurrences in a single individual counted. Because months were calculated as 28 days, the periods actually equate to 48 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary Adverse Event Rates Over Time</measure>
    <time_frame>through 264 Weeks</time_frame>
    <description>Patient year (PY) refers to duration in study, calculated from first active drug intake to last safety assessment available + 1. Patient year rates with confidence interval were calculated for adverse events of interest in evaluating the long-term safety of the product being studied.
Abbreviations include the following: adverse event (AE), adverse event of special interest (AESI), gastrointestinal (GI), serious adverse event (SAE), and investigational product (IP). Hypersensitivity events were defined as AEs that occurred during or within 24 hours of IP infusion and were not deemed &quot;unrelated&quot; to trial treatment by the investigator. This definition includes all types of AEs, regardless of whether or not they were consistent with hypersensitivity.
Medical confirmation of the AESI &quot;GI perforation&quot; was based on medical adjudication of events captured by the GI Perforation Standardised MedDRA Queries (SMQs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Death Rate Over Time</measure>
    <time_frame>through 264 Weeks</time_frame>
    <description>Patient year (PY) refers to duration in study, calculated from first active drug intake to last safety assessment available + 1.
To calculate the death rate, the total cumulative number of years that all participants were exposed to the drug, from first active drug intake to last safety assessment available + 1, was calculated as 2461.94. Since 10 participants died during that time, the death rate per year was not informative (0.00). Therefore, the overall death rate was calculated with the confidence interval based on events per 100 patient years exposure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants Showing Improvement in Rheumatoid Arthritis Symptoms Over Time, Through 264 Weeks</measure>
    <time_frame>through 264 Weeks</time_frame>
    <description>The American College of Rheumatology (ACR) established certain criteria to measure improvement in rheumatoid arthritis symptoms that include tender or swollen joint counts and five other criteria, including acute phase reactant, patient assessment, physician assessment, pain scale, and disability/functional questionnaire.
Clinical trials use the ACR Score, based on those criteria, as a standard for reporting different degrees of improvement in rheumatoid arthritis symptoms.
Scores on the ACR scale may be up to ACR100 because the number after &quot;ACR&quot; is the percent of improvement in tender or swollen joint counts as well as in three of the other five criteria. Clinical trials determine the percentage of participants who achieve that score - that percentage of improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Classified as Responders by Disease Activity Scores Over Time, Through 264 Weeks</measure>
    <time_frame>through 264 Weeks</time_frame>
    <description>The disease activity score 28 (DAS28) is a combined index for measuring disease activity in rheumatic arthritis (RA) that includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The DAS28 scale ranges from 0 to 10, where lower scores represent less disease activity. Participants with DAS28 scores less than 2.6 were categorized as responders with remission and those with DAS 28 scores of 3.2 or less were categorized as responders with low disease activity (LDA). The percentage of participants classified as responders in each category was recorded over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Classified as Responders by EULAR Response Over Time, Through 264 Weeks</measure>
    <time_frame>through 264 Weeks</time_frame>
    <description>Participants were classified as responders based on a European League Against Rheumatism (EULAR) response of Good or Moderate. Comparing the DAS28 from one patient on two different time points, it is possible to define improvement or response. The EULAR response criteria take into consideration both the first score and the change in score in order to classify them as good response, moderate response or no response. The percentage of participants who were classified as responders was recorded, as posted below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Scores for Swollen and Tender Joint Counts Over Time, Through 264 Weeks</measure>
    <time_frame>through 264 Weeks</time_frame>
    <description>Swollen joint count (SJC) includes an assessment of 66 joints, and tender joint count (TJC) include an assessment of 68 joints. Joint prosthesis, arthrodesis or fused joints were not considered. Joints were assessed and classified as swollen/not swollen, and tender/not tender, by pressure and joint manipulation on physical examination. Change from Baseline in the SJC and TJC were calculated at given time points, and a negative change indicates improvement.
A small proportion of participants in the all-exposure population reduced or stopped their oral corticosteroid use due to sustained efficacy (defined as at least a 50% improvement in both swollen joint count (SJC) and tender joint count (TJC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Scores for Health Assessment Questionnaire − Disability Index Over Time, Through 264 Weeks</measure>
    <time_frame>through 264 Weeks</time_frame>
    <description>The Stanford Health Assessment Questionnaire - Disability Index (HAQ-DI) is a questionnaire specific for rheumatoid arthritis with 8 component sets (domains): dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Each domain has 2-3 questions (for a total of 20) that participants answer with categorical answers enumerated as a scale of 0-3, where 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do.
To calculate the HAQ-DI the patient must have a domain score for at least 6 of the eight domains. The HAQ-DI is the sum of the domain scores, divided by the number of domains that have a score (in range 6-8). The resulting HAQ-DI scores are on a scale that ranges from 0 to 3, where 0=lowest level of difficulty and 3=highest level of difficulty. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Scores for Patient's Global Assessment of Disease Activity Over Time, Through 264 Weeks</measure>
    <time_frame>through 264 Weeks</time_frame>
    <description>Patient's global assessment of disease activity is the patient's overall assessment of their disease activity during specified time periods on a 100 mm horizontal visual analogue scale (VAS). The left-hand extreme of the line was described as &quot;no disease activity&quot; (symptom-free and no arthritis symptoms) and the right-hand extreme as &quot;maximum disease activity&quot; (maximum arthritis disease activity). Change from baseline was calculated for given periods, and a negative change indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Scores for Physician's Global Assessment of Disease Activity Over Time, Through 264 Weeks</measure>
    <time_frame>through 264 Weeks</time_frame>
    <description>Physician's global assessment of disease activity is the treating physician's assessment of the patient's current disease activity on a 100 mm horizontal visual analogue scale (VAS). The extreme left end of the line was described as &quot;no disease activity&quot; (symptom-free and no arthritis symptoms) and the extreme right end as &quot;maximum disease activity&quot;. Change from baseline was calculated for given periods, and a negative change indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Scores for Patient's Level of Pain Over Time, Through 264 Weeks</measure>
    <time_frame>through 264 Weeks</time_frame>
    <description>The patient's assessment of the patient's current level of pain on a 100 mm horizontal VAS was recorded. The extreme left end of the line was described as &quot;no pain&quot; and the extreme right end as &quot;unbearable pain&quot;. Change from baseline was calculated for given periods, and a negative change indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least a 5-point Improvement From Baseline in Quality of Life Measure for Fatigue Over Time, Through 264 Weeks</measure>
    <time_frame>through 264 Weeks</time_frame>
    <description>Quality of life is measured using the sub-scale for Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F). The assessment was originally developed for chronic illnesses and is now widely used for patients with rheumatoid arthritis.
FACIT-F is a 13-item questionnaire. Participants score each item on a 5-point scale: 0 (Not at all) to 4 (Very much), for a highest possible score of 52. The responses are transformed into a FACIT-F score, where a higher score reflects an improvement. The percentage of participants with at least a 5-point improvement from baseline in the Facit-F score is shown at categorical time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least a 5-point Improvement From Baseline in Quality of Life Using the 36-Item Short-Form Health Survey (SF-36) Over Time, Through 264 Weeks</measure>
    <time_frame>through 264 Weeks</time_frame>
    <description>The SF-36 Health Survey is a standardized questionnaire consisting of 36 questions that measures patient-reported symptoms on 8 dimensions; it is used to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL. The percentage of participants with at least a 5-point improvement from baseline is presented for each subscale.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">538</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Tocilizumab 8 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants received tocilizumab 8 mg/kg to a maximum of 800 mg, administered by intravenous (IV) infusion over one hour, every 4 weeks. Concomitant therapies were limited to dosage and administration constraints detailed in the protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab (myeloma receptor antibody [MRA]) was supplied in sterile solution of 20 mg TCZ/mL for aseptic preparation of infusion bags for IV administration.</description>
    <arm_group_label>Tocilizumab 8 mg/kg</arm_group_label>
    <other_name>RoActemra</other_name>
    <other_name>Actemra</other_name>
    <other_name>Tocilizumab (MRA)</other_name>
    <other_name>TCZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have completed participation in the Phase III study WA17822 (NCT00106548)
             in adult rheumatoid arthritis.

        Exclusion Criteria:

          -  Treatment with any investigational agent since the last administration of study drug
             in WA17822.

          -  Treatment with intravenous (IV) gammaglobulin, plasmapheresis, or Prosorba column
             since the last administration of study drug in WA17822.

          -  Treatment with an anti-tumor necrosis factor or anti-interleukin-1 agent, or a T cell
             costimulation modulator since the last administration of study drug in WA17822.

          -  Previous treatment with any cell-depleting therapies.

          -  Parenteral, intramuscular, or intra-articular corticosteroids within 6 weeks prior to
             baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>1405</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>C1428DQG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <zip>5041</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maroochydore</city>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shenton Park</city>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>04027-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7R 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 3R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sainte-foy</city>
        <state>Quebec</state>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Bramstedt</city>
        <zip>24576</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baden-baden</city>
        <zip>76530</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <zip>91056</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koeln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <zip>852</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuen Mun</city>
        <zip>852</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pécs</city>
        <zip>7632</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cona (ferrara)</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gazzi</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <zip>07760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <zip>44620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Luis Potosi</city>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>258499</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Piestany</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Switzerland</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2008</study_first_submitted>
  <study_first_submitted_qc>July 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2008</study_first_posted>
  <results_first_submitted>July 17, 2013</results_first_submitted>
  <results_first_submitted_qc>October 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2013</results_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tocilizumab 8 mg/kg</title>
          <description>Patients received tocilizumab (TCZ) 8 mg/kg intravenously every 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="538"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="355"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Therapeutic Response</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Treatment</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to Return</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All-exposure population: All patients who entered the study and received at least one dose of tocilizumab at any time. Baseline was defined as the first dose of study drug, whether that occurred in the WA17822 study or the WA18695 study.</population>
      <group_list>
        <group group_id="B1">
          <title>Tocilizumab 8 mg/kg</title>
          <description>Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="538"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.8" spread="12.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Event (AE) Summary Over Time</title>
        <description>The number of participants experiencing at least one adverse event (AE) is recorded for each 12-month time period, with multiple occurrences in a single individual counted. Because months were calculated as 28 days, the periods actually equate to 48 weeks.</description>
        <time_frame>through 264 Weeks</time_frame>
        <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time.</population>
        <group_list>
          <group group_id="O1">
            <title>Months 0 - 12</title>
            <description>Participants with scores during Months 0-12, which equates to baseline through Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Months 13 − 24</title>
            <description>Participants with scores during Months 13 − 24, which equates to Weeks 49-96.</description>
          </group>
          <group group_id="O3">
            <title>Months 25 - 36</title>
            <description>Participants with scores during Months 25 - 36, which equates to Weeks 97-144.</description>
          </group>
          <group group_id="O4">
            <title>Months 37 − 48</title>
            <description>Participants with scores during Months 37 − 48, which equates to Weeks 145-192.</description>
          </group>
          <group group_id="O5">
            <title>Months Greater Than 48</title>
            <description>Participants with scores during Months greater than 48, which equates to Weeks 193-264.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event (AE) Summary Over Time</title>
          <description>The number of participants experiencing at least one adverse event (AE) is recorded for each 12-month time period, with multiple occurrences in a single individual counted. Because months were calculated as 28 days, the periods actually equate to 48 weeks.</description>
          <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="509"/>
                <count group_id="O3" value="463"/>
                <count group_id="O4" value="434"/>
                <count group_id="O5" value="414"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Experienced an adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="433"/>
                    <measurement group_id="O2" value="390"/>
                    <measurement group_id="O3" value="333"/>
                    <measurement group_id="O4" value="294"/>
                    <measurement group_id="O5" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Experienced a serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Experienced AE leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Showing Improvement in Rheumatoid Arthritis Symptoms Over Time, Through 264 Weeks</title>
        <description>The American College of Rheumatology (ACR) established certain criteria to measure improvement in rheumatoid arthritis symptoms that include tender or swollen joint counts and five other criteria, including acute phase reactant, patient assessment, physician assessment, pain scale, and disability/functional questionnaire.
Clinical trials use the ACR Score, based on those criteria, as a standard for reporting different degrees of improvement in rheumatoid arthritis symptoms.
Scores on the ACR scale may be up to ACR100 because the number after “ACR” is the percent of improvement in tender or swollen joint counts as well as in three of the other five criteria. Clinical trials determine the percentage of participants who achieve that score – that percentage of improvement.</description>
        <time_frame>through 264 Weeks</time_frame>
        <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab, with a score at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Week 24</title>
            <description>Participants with scores at 24 weeks post-baseline.</description>
          </group>
          <group group_id="O2">
            <title>Week 48</title>
            <description>Participants with scores at 48 weeks post-baseline.</description>
          </group>
          <group group_id="O3">
            <title>Week 108</title>
            <description>Participants with scores at 108 weeks post-baseline.</description>
          </group>
          <group group_id="O4">
            <title>Week 156</title>
            <description>Participants with scores at 156 weeks post-baseline.</description>
          </group>
          <group group_id="O5">
            <title>Week 204</title>
            <description>Participants with scores at 204 weeks post-baseline.</description>
          </group>
          <group group_id="O6">
            <title>Week 264</title>
            <description>Participants with scores at 264 weeks post-baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Showing Improvement in Rheumatoid Arthritis Symptoms Over Time, Through 264 Weeks</title>
          <description>The American College of Rheumatology (ACR) established certain criteria to measure improvement in rheumatoid arthritis symptoms that include tender or swollen joint counts and five other criteria, including acute phase reactant, patient assessment, physician assessment, pain scale, and disability/functional questionnaire.
Clinical trials use the ACR Score, based on those criteria, as a standard for reporting different degrees of improvement in rheumatoid arthritis symptoms.
Scores on the ACR scale may be up to ACR100 because the number after “ACR” is the percent of improvement in tender or swollen joint counts as well as in three of the other five criteria. Clinical trials determine the percentage of participants who achieve that score – that percentage of improvement.</description>
          <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab, with a score at the given time point.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="480"/>
                <count group_id="O3" value="422"/>
                <count group_id="O4" value="413"/>
                <count group_id="O5" value="387"/>
                <count group_id="O6" value="367"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2"/>
                    <measurement group_id="O2" value="76.0"/>
                    <measurement group_id="O3" value="81.2"/>
                    <measurement group_id="O4" value="83.3"/>
                    <measurement group_id="O5" value="82.2"/>
                    <measurement group_id="O6" value="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2"/>
                    <measurement group_id="O2" value="50.6"/>
                    <measurement group_id="O3" value="58.1"/>
                    <measurement group_id="O4" value="59.6"/>
                    <measurement group_id="O5" value="62.5"/>
                    <measurement group_id="O6" value="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                    <measurement group_id="O2" value="27.1"/>
                    <measurement group_id="O3" value="38.2"/>
                    <measurement group_id="O4" value="41.9"/>
                    <measurement group_id="O5" value="42.1"/>
                    <measurement group_id="O6" value="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="5.2"/>
                    <measurement group_id="O3" value="11.3"/>
                    <measurement group_id="O4" value="15.3"/>
                    <measurement group_id="O5" value="16.8"/>
                    <measurement group_id="O6" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Classified as Responders by Disease Activity Scores Over Time, Through 264 Weeks</title>
        <description>The disease activity score 28 (DAS28) is a combined index for measuring disease activity in rheumatic arthritis (RA) that includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The DAS28 scale ranges from 0 to 10, where lower scores represent less disease activity. Participants with DAS28 scores less than 2.6 were categorized as responders with remission and those with DAS 28 scores of 3.2 or less were categorized as responders with low disease activity (LDA). The percentage of participants classified as responders in each category was recorded over time.</description>
        <time_frame>through 264 Weeks</time_frame>
        <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time.</population>
        <group_list>
          <group group_id="O1">
            <title>Week 24</title>
            <description>Participants with scores at 24 weeks post-baseline.</description>
          </group>
          <group group_id="O2">
            <title>Week 48</title>
            <description>Participants with scores at 48 weeks post-baseline.</description>
          </group>
          <group group_id="O3">
            <title>Week 108</title>
            <description>Participants with scores at 108 weeks post-baseline.</description>
          </group>
          <group group_id="O4">
            <title>Week 156</title>
            <description>Participants with scores at 156 weeks post-baseline.</description>
          </group>
          <group group_id="O5">
            <title>Week 204</title>
            <description>Participants with scores at 204 weeks post-baseline.</description>
          </group>
          <group group_id="O6">
            <title>Week 264</title>
            <description>Participants with scores at 264 weeks post-baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Classified as Responders by Disease Activity Scores Over Time, Through 264 Weeks</title>
          <description>The disease activity score 28 (DAS28) is a combined index for measuring disease activity in rheumatic arthritis (RA) that includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The DAS28 scale ranges from 0 to 10, where lower scores represent less disease activity. Participants with DAS28 scores less than 2.6 were categorized as responders with remission and those with DAS 28 scores of 3.2 or less were categorized as responders with low disease activity (LDA). The percentage of participants classified as responders in each category was recorded over time.</description>
          <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="470"/>
                <count group_id="O3" value="430"/>
                <count group_id="O4" value="410"/>
                <count group_id="O5" value="381"/>
                <count group_id="O6" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders with Remission (DAS&lt;2.6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="43.0"/>
                    <measurement group_id="O3" value="53.7"/>
                    <measurement group_id="O4" value="54.9"/>
                    <measurement group_id="O5" value="57.2"/>
                    <measurement group_id="O6" value="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders with Low Disease Activity (DAS&lt;/= 3.2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="57.7"/>
                    <measurement group_id="O3" value="67.0"/>
                    <measurement group_id="O4" value="71.2"/>
                    <measurement group_id="O5" value="70.6"/>
                    <measurement group_id="O6" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Classified as Responders by EULAR Response Over Time, Through 264 Weeks</title>
        <description>Participants were classified as responders based on a European League Against Rheumatism (EULAR) response of Good or Moderate. Comparing the DAS28 from one patient on two different time points, it is possible to define improvement or response. The EULAR response criteria take into consideration both the first score and the change in score in order to classify them as good response, moderate response or no response. The percentage of participants who were classified as responders was recorded, as posted below.</description>
        <time_frame>through 264 Weeks</time_frame>
        <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time.</population>
        <group_list>
          <group group_id="O1">
            <title>Week 24</title>
            <description>Participants with scores at 24 weeks post-baseline.</description>
          </group>
          <group group_id="O2">
            <title>Week 48</title>
            <description>Participants with scores at 48 weeks post-baseline.</description>
          </group>
          <group group_id="O3">
            <title>Week 108</title>
            <description>Participants with scores at 108 weeks post-baseline.</description>
          </group>
          <group group_id="O4">
            <title>Week 156</title>
            <description>Participants with scores at 156 weeks post-baseline.</description>
          </group>
          <group group_id="O5">
            <title>Week 204</title>
            <description>Participants with scores at 204 weeks post-baseline.</description>
          </group>
          <group group_id="O6">
            <title>Week 264</title>
            <description>Participants with scores at 264 weeks post-baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Classified as Responders by EULAR Response Over Time, Through 264 Weeks</title>
          <description>Participants were classified as responders based on a European League Against Rheumatism (EULAR) response of Good or Moderate. Comparing the DAS28 from one patient on two different time points, it is possible to define improvement or response. The EULAR response criteria take into consideration both the first score and the change in score in order to classify them as good response, moderate response or no response. The percentage of participants who were classified as responders was recorded, as posted below.</description>
          <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="514"/>
                <count group_id="O2" value="468"/>
                <count group_id="O3" value="429"/>
                <count group_id="O4" value="409"/>
                <count group_id="O5" value="380"/>
                <count group_id="O6" value="362"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EULAR Good Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2"/>
                    <measurement group_id="O2" value="56.6"/>
                    <measurement group_id="O3" value="65.5"/>
                    <measurement group_id="O4" value="70.9"/>
                    <measurement group_id="O5" value="69.5"/>
                    <measurement group_id="O6" value="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EULAR Moderate Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1"/>
                    <measurement group_id="O2" value="39.1"/>
                    <measurement group_id="O3" value="29.8"/>
                    <measurement group_id="O4" value="25.9"/>
                    <measurement group_id="O5" value="26.8"/>
                    <measurement group_id="O6" value="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Scores for Swollen and Tender Joint Counts Over Time, Through 264 Weeks</title>
        <description>Swollen joint count (SJC) includes an assessment of 66 joints, and tender joint count (TJC) include an assessment of 68 joints. Joint prosthesis, arthrodesis or fused joints were not considered. Joints were assessed and classified as swollen/not swollen, and tender/not tender, by pressure and joint manipulation on physical examination. Change from Baseline in the SJC and TJC were calculated at given time points, and a negative change indicates improvement.
A small proportion of participants in the all-exposure population reduced or stopped their oral corticosteroid use due to sustained efficacy (defined as at least a 50% improvement in both swollen joint count (SJC) and tender joint count (TJC).</description>
        <time_frame>through 264 Weeks</time_frame>
        <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Week 24</title>
            <description>Participants with scores at 24 weeks post-baseline.</description>
          </group>
          <group group_id="O2">
            <title>Week 48</title>
            <description>Participants with scores at 48 weeks post-baseline.</description>
          </group>
          <group group_id="O3">
            <title>Week 108</title>
            <description>Participants with scores at 108 weeks post-baseline.</description>
          </group>
          <group group_id="O4">
            <title>Week 156</title>
            <description>Participants with scores at 156 weeks post-baseline.</description>
          </group>
          <group group_id="O5">
            <title>Week 204</title>
            <description>Participants with scores at 204 weeks post-baseline.</description>
          </group>
          <group group_id="O6">
            <title>Week 264</title>
            <description>Participants with scores at 264 weeks post-baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Scores for Swollen and Tender Joint Counts Over Time, Through 264 Weeks</title>
          <description>Swollen joint count (SJC) includes an assessment of 66 joints, and tender joint count (TJC) include an assessment of 68 joints. Joint prosthesis, arthrodesis or fused joints were not considered. Joints were assessed and classified as swollen/not swollen, and tender/not tender, by pressure and joint manipulation on physical examination. Change from Baseline in the SJC and TJC were calculated at given time points, and a negative change indicates improvement.
A small proportion of participants in the all-exposure population reduced or stopped their oral corticosteroid use due to sustained efficacy (defined as at least a 50% improvement in both swollen joint count (SJC) and tender joint count (TJC).</description>
          <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.</population>
          <units>Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="532"/>
                <count group_id="O2" value="506"/>
                <count group_id="O3" value="454"/>
                <count group_id="O4" value="422"/>
                <count group_id="O5" value="405"/>
                <count group_id="O6" value="371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Swollen Joint Count (SJC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.7" spread="11.50"/>
                    <measurement group_id="O2" value="-13.6" spread="11.04"/>
                    <measurement group_id="O3" value="-15.6" spread="11.51"/>
                    <measurement group_id="O4" value="-16.2" spread="11.46"/>
                    <measurement group_id="O5" value="-16.2" spread="11.48"/>
                    <measurement group_id="O6" value="-16.5" spread="11.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender Joint Count (TJC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.4" spread="14.82"/>
                    <measurement group_id="O2" value="-20.3" spread="15.12"/>
                    <measurement group_id="O3" value="-23.1" spread="15.82"/>
                    <measurement group_id="O4" value="-23.8" spread="16.14"/>
                    <measurement group_id="O5" value="-23.8" spread="15.89"/>
                    <measurement group_id="O6" value="-24.8" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Scores for Health Assessment Questionnaire − Disability Index Over Time, Through 264 Weeks</title>
        <description>The Stanford Health Assessment Questionnaire - Disability Index (HAQ-DI) is a questionnaire specific for rheumatoid arthritis with 8 component sets (domains): dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Each domain has 2-3 questions (for a total of 20) that participants answer with categorical answers enumerated as a scale of 0-3, where 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do.
To calculate the HAQ-DI the patient must have a domain score for at least 6 of the eight domains. The HAQ-DI is the sum of the domain scores, divided by the number of domains that have a score (in range 6-8). The resulting HAQ-DI scores are on a scale that ranges from 0 to 3, where 0=lowest level of difficulty and 3=highest level of difficulty. A negative change from baseline indicates improvement.</description>
        <time_frame>through 264 Weeks</time_frame>
        <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Week 24</title>
            <description>Participants with scores at 24 weeks post-baseline.</description>
          </group>
          <group group_id="O2">
            <title>Week 48</title>
            <description>Participants with scores at 48 weeks post-baseline.</description>
          </group>
          <group group_id="O3">
            <title>Week 108</title>
            <description>Participants with scores at 108 weeks post-baseline.</description>
          </group>
          <group group_id="O4">
            <title>Week 156</title>
            <description>Participants with scores at 156 weeks post-baseline.</description>
          </group>
          <group group_id="O5">
            <title>Week 204</title>
            <description>Participants with scores at 204 weeks post-baseline.</description>
          </group>
          <group group_id="O6">
            <title>Week 264</title>
            <description>Participants with scores at 264 weeks post-baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Scores for Health Assessment Questionnaire − Disability Index Over Time, Through 264 Weeks</title>
          <description>The Stanford Health Assessment Questionnaire - Disability Index (HAQ-DI) is a questionnaire specific for rheumatoid arthritis with 8 component sets (domains): dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Each domain has 2-3 questions (for a total of 20) that participants answer with categorical answers enumerated as a scale of 0-3, where 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do.
To calculate the HAQ-DI the patient must have a domain score for at least 6 of the eight domains. The HAQ-DI is the sum of the domain scores, divided by the number of domains that have a score (in range 6-8). The resulting HAQ-DI scores are on a scale that ranges from 0 to 3, where 0=lowest level of difficulty and 3=highest level of difficulty. A negative change from baseline indicates improvement.</description>
          <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="445"/>
                <count group_id="O2" value="408"/>
                <count group_id="O3" value="376"/>
                <count group_id="O4" value="349"/>
                <count group_id="O5" value="332"/>
                <count group_id="O6" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.582"/>
                    <measurement group_id="O2" value="-0.53" spread="0.614"/>
                    <measurement group_id="O3" value="-0.59" spread="0.636"/>
                    <measurement group_id="O4" value="-0.61" spread="0.655"/>
                    <measurement group_id="O5" value="-0.65" spread="0.661"/>
                    <measurement group_id="O6" value="-0.62" spread="0.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Scores for Patient's Global Assessment of Disease Activity Over Time, Through 264 Weeks</title>
        <description>Patient’s global assessment of disease activity is the patient’s overall assessment of their disease activity during specified time periods on a 100 mm horizontal visual analogue scale (VAS). The left-hand extreme of the line was described as “no disease activity” (symptom-free and no arthritis symptoms) and the right-hand extreme as “maximum disease activity” (maximum arthritis disease activity). Change from baseline was calculated for given periods, and a negative change indicates improvement.</description>
        <time_frame>through 264 Weeks</time_frame>
        <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Week 24</title>
            <description>Participants with scores at 24 weeks post-baseline.</description>
          </group>
          <group group_id="O2">
            <title>Week 48</title>
            <description>Participants with scores at 48 weeks post-baseline.</description>
          </group>
          <group group_id="O3">
            <title>Week 108</title>
            <description>Participants with scores at 108 weeks post-baseline.</description>
          </group>
          <group group_id="O4">
            <title>Week 156</title>
            <description>Participants with scores at 156 weeks post-baseline.</description>
          </group>
          <group group_id="O5">
            <title>Week 204</title>
            <description>Participants with scores at 204 weeks post-baseline.</description>
          </group>
          <group group_id="O6">
            <title>Week 264</title>
            <description>Participants with scores at 264 weeks post-baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Scores for Patient's Global Assessment of Disease Activity Over Time, Through 264 Weeks</title>
          <description>Patient’s global assessment of disease activity is the patient’s overall assessment of their disease activity during specified time periods on a 100 mm horizontal visual analogue scale (VAS). The left-hand extreme of the line was described as “no disease activity” (symptom-free and no arthritis symptoms) and the right-hand extreme as “maximum disease activity” (maximum arthritis disease activity). Change from baseline was calculated for given periods, and a negative change indicates improvement.</description>
          <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
                <count group_id="O2" value="479"/>
                <count group_id="O3" value="442"/>
                <count group_id="O4" value="414"/>
                <count group_id="O5" value="387"/>
                <count group_id="O6" value="367"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.6" spread="26.87"/>
                    <measurement group_id="O2" value="-30.3" spread="27.71"/>
                    <measurement group_id="O3" value="-31.1" spread="27.65"/>
                    <measurement group_id="O4" value="-31.6" spread="26.74"/>
                    <measurement group_id="O5" value="-33.0" spread="26.83"/>
                    <measurement group_id="O6" value="-32.9" spread="27.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Scores for Physician's Global Assessment of Disease Activity Over Time, Through 264 Weeks</title>
        <description>Physician’s global assessment of disease activity is the treating physician’s assessment of the patient’s current disease activity on a 100 mm horizontal visual analogue scale (VAS). The extreme left end of the line was described as “no disease activity” (symptom-free and no arthritis symptoms) and the extreme right end as “maximum disease activity”. Change from baseline was calculated for given periods, and a negative change indicates improvement.</description>
        <time_frame>through 264 Weeks</time_frame>
        <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Week 24</title>
            <description>Participants with scores at 24 weeks post-baseline.</description>
          </group>
          <group group_id="O2">
            <title>Week 48</title>
            <description>Participants with scores at 48 weeks post-baseline.</description>
          </group>
          <group group_id="O3">
            <title>Week 108</title>
            <description>Participants with scores at 108 weeks post-baseline.</description>
          </group>
          <group group_id="O4">
            <title>Week 156</title>
            <description>Participants with scores at 156 weeks post-baseline.</description>
          </group>
          <group group_id="O5">
            <title>Week 204</title>
            <description>Participants with scores at 204 weeks post-baseline.</description>
          </group>
          <group group_id="O6">
            <title>Week 264</title>
            <description>Participants with scores at 264 weeks post-baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Scores for Physician's Global Assessment of Disease Activity Over Time, Through 264 Weeks</title>
          <description>Physician’s global assessment of disease activity is the treating physician’s assessment of the patient’s current disease activity on a 100 mm horizontal visual analogue scale (VAS). The extreme left end of the line was described as “no disease activity” (symptom-free and no arthritis symptoms) and the extreme right end as “maximum disease activity”. Change from baseline was calculated for given periods, and a negative change indicates improvement.</description>
          <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
                <count group_id="O2" value="479"/>
                <count group_id="O3" value="439"/>
                <count group_id="O4" value="416"/>
                <count group_id="O5" value="389"/>
                <count group_id="O6" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.8" spread="23.33"/>
                    <measurement group_id="O2" value="-38.1" spread="23.77"/>
                    <measurement group_id="O3" value="-41.1" spread="23.79"/>
                    <measurement group_id="O4" value="-43.2" spread="23.26"/>
                    <measurement group_id="O5" value="-44.8" spread="22.66"/>
                    <measurement group_id="O6" value="-44.4" spread="23.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Scores for Patient's Level of Pain Over Time, Through 264 Weeks</title>
        <description>The patient’s assessment of the patient's current level of pain on a 100 mm horizontal VAS was recorded. The extreme left end of the line was described as “no pain” and the extreme right end as “unbearable pain”. Change from baseline was calculated for given periods, and a negative change indicates improvement.</description>
        <time_frame>through 264 Weeks</time_frame>
        <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Week 24</title>
            <description>Participants with scores at 24 weeks post-baseline.</description>
          </group>
          <group group_id="O2">
            <title>Week 48</title>
            <description>Participants with scores at 48 weeks post-baseline.</description>
          </group>
          <group group_id="O3">
            <title>Week 108</title>
            <description>Participants with scores at 108 weeks post-baseline.</description>
          </group>
          <group group_id="O4">
            <title>Week 156</title>
            <description>Participants with scores at 156 weeks post-baseline.</description>
          </group>
          <group group_id="O5">
            <title>Week 204</title>
            <description>Participants with scores at 204 weeks post-baseline.</description>
          </group>
          <group group_id="O6">
            <title>Week 264</title>
            <description>Participants with scores at 264 weeks post-baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Scores for Patient's Level of Pain Over Time, Through 264 Weeks</title>
          <description>The patient’s assessment of the patient's current level of pain on a 100 mm horizontal VAS was recorded. The extreme left end of the line was described as “no pain” and the extreme right end as “unbearable pain”. Change from baseline was calculated for given periods, and a negative change indicates improvement.</description>
          <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
                <count group_id="O2" value="479"/>
                <count group_id="O3" value="442"/>
                <count group_id="O4" value="414"/>
                <count group_id="O5" value="388"/>
                <count group_id="O6" value="367"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.7" spread="26.38"/>
                    <measurement group_id="O2" value="-26.7" spread="27.27"/>
                    <measurement group_id="O3" value="-28.0" spread="26.33"/>
                    <measurement group_id="O4" value="-28.1" spread="25.99"/>
                    <measurement group_id="O5" value="-29.5" spread="26.98"/>
                    <measurement group_id="O6" value="-29.2" spread="26.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary Adverse Event Rates Over Time</title>
        <description>Patient year (PY) refers to duration in study, calculated from first active drug intake to last safety assessment available + 1. Patient year rates with confidence interval were calculated for adverse events of interest in evaluating the long-term safety of the product being studied.
Abbreviations include the following: adverse event (AE), adverse event of special interest (AESI), gastrointestinal (GI), serious adverse event (SAE), and investigational product (IP). Hypersensitivity events were defined as AEs that occurred during or within 24 hours of IP infusion and were not deemed “unrelated” to trial treatment by the investigator. This definition includes all types of AEs, regardless of whether or not they were consistent with hypersensitivity.
Medical confirmation of the AESI &quot;GI perforation&quot; was based on medical adjudication of events captured by the GI Perforation Standardised MedDRA Queries (SMQs).</description>
        <time_frame>through 264 Weeks</time_frame>
        <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time.</population>
        <group_list>
          <group group_id="O1">
            <title>Months 0 - 12</title>
            <description>Participants with scores during Months 0-12, which equates to baseline through Week 48 (Total PY=486.34).</description>
          </group>
          <group group_id="O2">
            <title>Months 13 − 24</title>
            <description>Participants with scores during Months 13 − 24, which equates to Weeks 49-96 (Total PY=444.49).</description>
          </group>
          <group group_id="O3">
            <title>Months 25 - 36</title>
            <description>Participants with scores during Months 25 - 36, which equates to Weeks 97-144 (Total PY=410.93).</description>
          </group>
          <group group_id="O4">
            <title>Months 37 − 48</title>
            <description>Participants with scores during Months 37 − 48, which equates to Weeks 145-192 (Total PY=388.25).</description>
          </group>
          <group group_id="O5">
            <title>Months Greater Than 48</title>
            <description>Participants with scores during Months greater than 48, which equates to Weeks 193-264 (Total PY=731.93).</description>
          </group>
        </group_list>
        <measure>
          <title>Summary Adverse Event Rates Over Time</title>
          <description>Patient year (PY) refers to duration in study, calculated from first active drug intake to last safety assessment available + 1. Patient year rates with confidence interval were calculated for adverse events of interest in evaluating the long-term safety of the product being studied.
Abbreviations include the following: adverse event (AE), adverse event of special interest (AESI), gastrointestinal (GI), serious adverse event (SAE), and investigational product (IP). Hypersensitivity events were defined as AEs that occurred during or within 24 hours of IP infusion and were not deemed “unrelated” to trial treatment by the investigator. This definition includes all types of AEs, regardless of whether or not they were consistent with hypersensitivity.
Medical confirmation of the AESI &quot;GI perforation&quot; was based on medical adjudication of events captured by the GI Perforation Standardised MedDRA Queries (SMQs).</description>
          <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time.</population>
          <units>Adverse Events per 100 Patient Years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="509"/>
                <count group_id="O3" value="463"/>
                <count group_id="O4" value="434"/>
                <count group_id="O5" value="414"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total AE rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393.76" lower_limit="376.32" upper_limit="411.80"/>
                    <measurement group_id="O2" value="286.17" lower_limit="270.66" upper_limit="302.34"/>
                    <measurement group_id="O3" value="260.14" lower_limit="244.78" upper_limit="276.22"/>
                    <measurement group_id="O4" value="249.84" lower_limit="234.36" upper_limit="266.07"/>
                    <measurement group_id="O5" value="212.04" lower_limit="201.62" upper_limit="222.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total SAE rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.54" lower_limit="9.59" upper_limit="16.11"/>
                    <measurement group_id="O2" value="13.05" lower_limit="9.91" upper_limit="16.87"/>
                    <measurement group_id="O3" value="18.74" lower_limit="14.79" upper_limit="23.42"/>
                    <measurement group_id="O4" value="12.62" lower_limit="9.34" upper_limit="16.69"/>
                    <measurement group_id="O5" value="13.12" lower_limit="10.62" upper_limit="16.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rate for AEs leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.14" lower_limit="3.33" upper_limit="7.59"/>
                    <measurement group_id="O2" value="3.82" lower_limit="2.23" upper_limit="6.12"/>
                    <measurement group_id="O3" value="5.35" lower_limit="3.36" upper_limit="8.11"/>
                    <measurement group_id="O4" value="2.06" lower_limit="0.89" upper_limit="4.06"/>
                    <measurement group_id="O5" value="4.37" lower_limit="2.99" upper_limit="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI All Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.94" lower_limit="84.57" upper_limit="101.92"/>
                    <measurement group_id="O2" value="87.52" lower_limit="79.03" upper_limit="96.66"/>
                    <measurement group_id="O3" value="87.36" lower_limit="78.56" upper_limit="96.88"/>
                    <measurement group_id="O4" value="87.32" lower_limit="78.27" upper_limit="97.12"/>
                    <measurement group_id="O5" value="72.82" lower_limit="66.77" upper_limit="79.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI Serious Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" lower_limit="1.88" upper_limit="5.34"/>
                    <measurement group_id="O2" value="2.47" lower_limit="1.24" upper_limit="4.43"/>
                    <measurement group_id="O3" value="5.60" lower_limit="3.55" upper_limit="8.40"/>
                    <measurement group_id="O4" value="3.35" lower_limit="1.78" upper_limit="5.73"/>
                    <measurement group_id="O5" value="3.55" lower_limit="2.32" upper_limit="5.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI Opportunistic infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">There were no opportunistic infections in this period.</measurement>
                    <measurement group_id="O2" value="0.22" lower_limit="0.01" upper_limit="1.25"/>
                    <measurement group_id="O3" value="0">There were no opportunistic infections in this period.</measurement>
                    <measurement group_id="O4" value="0.52" lower_limit="0.06" upper_limit="1.86"/>
                    <measurement group_id="O5" value="0.27" lower_limit="0.03" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI Hypersensitivity events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.35" lower_limit="22.90" upper_limit="32.41"/>
                    <measurement group_id="O2" value="9.90" lower_limit="7.19" upper_limit="13.29"/>
                    <measurement group_id="O3" value="5.35" lower_limit="3.36" upper_limit="8.11"/>
                    <measurement group_id="O4" value="3.86" lower_limit="2.16" upper_limit="6.37"/>
                    <measurement group_id="O5" value="4.10" lower_limit="2.77" upper_limit="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI Hepatic events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" lower_limit="0.05" upper_limit="1.49"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.25" upper_limit="2.30"/>
                    <measurement group_id="O3" value="0.49" lower_limit="0.06" upper_limit="1.76"/>
                    <measurement group_id="O4" value="1.03" lower_limit="0.28" upper_limit="2.64"/>
                    <measurement group_id="O5" value="0.68" lower_limit="0.22" upper_limit="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI Myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" lower_limit="0.13" upper_limit="1.80"/>
                    <measurement group_id="O2" value="0">There were no myocardial infarctions in this period.</measurement>
                    <measurement group_id="O3" value="0.24" lower_limit="0.01" upper_limit="1.36"/>
                    <measurement group_id="O4" value="0.77" lower_limit="0.16" upper_limit="2.26"/>
                    <measurement group_id="O5" value="0.27" lower_limit="0.03" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI Stroke, ischemic or hemorrhagic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" lower_limit="0.01" upper_limit="1.15"/>
                    <measurement group_id="O2" value="0.22" lower_limit="0.01" upper_limit="1.25"/>
                    <measurement group_id="O3" value="0.73" lower_limit="0.15" upper_limit="2.13"/>
                    <measurement group_id="O4" value="0.26" lower_limit="0.01" upper_limit="1.44"/>
                    <measurement group_id="O5" value="0.41" lower_limit="0.08" upper_limit="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI GI perforation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">There were no medically confirmed GI perforations in this period.</measurement>
                    <measurement group_id="O2" value="0">There were no medically confirmed GI perforations in this period.</measurement>
                    <measurement group_id="O3" value="0.49" lower_limit="0.06" upper_limit="1.76"/>
                    <measurement group_id="O4" value="0.26" lower_limit="0.01" upper_limit="1.44"/>
                    <measurement group_id="O5" value="0">There were no medically confirmed GI perforations in this period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI Malignancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0.45" upper_limit="2.69"/>
                    <measurement group_id="O2" value="1.80" lower_limit="0.78" upper_limit="3.55"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.27" upper_limit="2.49"/>
                    <measurement group_id="O4" value="0.77" lower_limit="0.16" upper_limit="2.26"/>
                    <measurement group_id="O5" value="1.50" lower_limit="0.75" upper_limit="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI Demyelinating disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" lower_limit="0.01" upper_limit="1.15"/>
                    <measurement group_id="O2" value="0">There were no demyelinating disorders in this period.</measurement>
                    <measurement group_id="O3" value="0">There were no demyelinating disorders in this period.</measurement>
                    <measurement group_id="O4" value="0">There were no demyelinating disorders in this period.</measurement>
                    <measurement group_id="O5" value="0">There were no demyelinating disorders in this period.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI Serious bleeding disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" lower_limit="0.13" upper_limit="1.80"/>
                    <measurement group_id="O2" value="0.45" lower_limit="0.05" upper_limit="1.63"/>
                    <measurement group_id="O3" value="0.49" lower_limit="0.06" upper_limit="1.76"/>
                    <measurement group_id="O4" value="0.26" lower_limit="0.01" upper_limit="1.44"/>
                    <measurement group_id="O5" value="0.68" lower_limit="0.22" upper_limit="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Death Rate Over Time</title>
        <description>Patient year (PY) refers to duration in study, calculated from first active drug intake to last safety assessment available + 1.
To calculate the death rate, the total cumulative number of years that all participants were exposed to the drug, from first active drug intake to last safety assessment available + 1, was calculated as 2461.94. Since 10 participants died during that time, the death rate per year was not informative (0.00). Therefore, the overall death rate was calculated with the confidence interval based on events per 100 patient years exposure.</description>
        <time_frame>through 264 Weeks</time_frame>
        <population>All exposure population, which included all participants who entered the study and received at least one dose of tocilizumab at any time.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab 8 mg/kg</title>
            <description>Patients received tocilizumab (TCZ) 8 mg/kg intravenously every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Death Rate Over Time</title>
          <description>Patient year (PY) refers to duration in study, calculated from first active drug intake to last safety assessment available + 1.
To calculate the death rate, the total cumulative number of years that all participants were exposed to the drug, from first active drug intake to last safety assessment available + 1, was calculated as 2461.94. Since 10 participants died during that time, the death rate per year was not informative (0.00). Therefore, the overall death rate was calculated with the confidence interval based on events per 100 patient years exposure.</description>
          <population>All exposure population, which included all participants who entered the study and received at least one dose of tocilizumab at any time.</population>
          <units>Deaths per 100 PY</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" lower_limit="0.19" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least a 5-point Improvement From Baseline in Quality of Life Measure for Fatigue Over Time, Through 264 Weeks</title>
        <description>Quality of life is measured using the sub-scale for Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F). The assessment was originally developed for chronic illnesses and is now widely used for patients with rheumatoid arthritis.
FACIT-F is a 13-item questionnaire. Participants score each item on a 5-point scale: 0 (Not at all) to 4 (Very much), for a highest possible score of 52. The responses are transformed into a FACIT-F score, where a higher score reflects an improvement. The percentage of participants with at least a 5-point improvement from baseline in the Facit-F score is shown at categorical time points.</description>
        <time_frame>through 264 Weeks</time_frame>
        <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Week 24</title>
            <description>Participants with scores at 24 weeks post-baseline.</description>
          </group>
          <group group_id="O2">
            <title>Week 48</title>
            <description>Participants with scores at 48 weeks post-baseline.</description>
          </group>
          <group group_id="O3">
            <title>Week 108</title>
            <description>Participants with scores at 108 weeks post-baseline.</description>
          </group>
          <group group_id="O4">
            <title>Week 156</title>
            <description>Participants with scores at 156 weeks post-baseline.</description>
          </group>
          <group group_id="O5">
            <title>Week 204</title>
            <description>Participants with scores at 204 weeks post-baseline.</description>
          </group>
          <group group_id="O6">
            <title>Week 264</title>
            <description>Participants with scores at 264 weeks post-baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 5-point Improvement From Baseline in Quality of Life Measure for Fatigue Over Time, Through 264 Weeks</title>
          <description>Quality of life is measured using the sub-scale for Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F). The assessment was originally developed for chronic illnesses and is now widely used for patients with rheumatoid arthritis.
FACIT-F is a 13-item questionnaire. Participants score each item on a 5-point scale: 0 (Not at all) to 4 (Very much), for a highest possible score of 52. The responses are transformed into a FACIT-F score, where a higher score reflects an improvement. The percentage of participants with at least a 5-point improvement from baseline in the Facit-F score is shown at categorical time points.</description>
          <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="523"/>
                <count group_id="O2" value="482"/>
                <count group_id="O3" value="444"/>
                <count group_id="O4" value="414"/>
                <count group_id="O5" value="390"/>
                <count group_id="O6" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0"/>
                    <measurement group_id="O2" value="58.7"/>
                    <measurement group_id="O3" value="61.5"/>
                    <measurement group_id="O4" value="62.3"/>
                    <measurement group_id="O5" value="60.0"/>
                    <measurement group_id="O6" value="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least a 5-point Improvement From Baseline in Quality of Life Using the 36-Item Short-Form Health Survey (SF-36) Over Time, Through 264 Weeks</title>
        <description>The SF-36 Health Survey is a standardized questionnaire consisting of 36 questions that measures patient-reported symptoms on 8 dimensions; it is used to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL. The percentage of participants with at least a 5-point improvement from baseline is presented for each subscale.</description>
        <time_frame>through 264 Weeks</time_frame>
        <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Week 24</title>
            <description>Participants with scores at 24 weeks post-baseline.</description>
          </group>
          <group group_id="O2">
            <title>Week 48</title>
            <description>Participants with scores at 48 weeks post-baseline.</description>
          </group>
          <group group_id="O3">
            <title>Week 108</title>
            <description>Participants with scores at 108 weeks post-baseline.</description>
          </group>
          <group group_id="O4">
            <title>Week 156</title>
            <description>Participants with scores at 156 weeks post-baseline.</description>
          </group>
          <group group_id="O5">
            <title>Week 204</title>
            <description>Participants with scores at 204 weeks post-baseline.</description>
          </group>
          <group group_id="O6">
            <title>Week 264</title>
            <description>Participants with scores at 264 weeks post-baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 5-point Improvement From Baseline in Quality of Life Using the 36-Item Short-Form Health Survey (SF-36) Over Time, Through 264 Weeks</title>
          <description>The SF-36 Health Survey is a standardized questionnaire consisting of 36 questions that measures patient-reported symptoms on 8 dimensions; it is used to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL. The percentage of participants with at least a 5-point improvement from baseline is presented for each subscale.</description>
          <population>All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="424"/>
                <count group_id="O3" value="395"/>
                <count group_id="O4" value="373"/>
                <count group_id="O5" value="344"/>
                <count group_id="O6" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2"/>
                    <measurement group_id="O2" value="46.2"/>
                    <measurement group_id="O3" value="48.6"/>
                    <measurement group_id="O4" value="49.9"/>
                    <measurement group_id="O5" value="49.7"/>
                    <measurement group_id="O6" value="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.8"/>
                    <measurement group_id="O2" value="69.1"/>
                    <measurement group_id="O3" value="71.1"/>
                    <measurement group_id="O4" value="71.3"/>
                    <measurement group_id="O5" value="73.3"/>
                    <measurement group_id="O6" value="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All-exposure population: All patients who entered the study and received at least 1 dose of tocilizumab at any time.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tocilizumab 8 mg/kg</title>
          <description>Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Anaemia of chronic disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Oesophageal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Perforation bile duct</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Bursitis infective staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Douglas' abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Endocarditis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Lung Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Proteus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Septic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Staphylococcal septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Dislocation of vertebra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Fractured ischium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Gas poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Incision site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Vascular bypass dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Lupus-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Muscle necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Breast cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Breast cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Colon cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Rectal cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer state unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Essential tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Mediastinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Rheumatoid lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Cutaneous vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Vericose vein</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Vasculitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="475" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="538"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="538"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

